Join us for an exclusive interview with Gareth Sheridan, CEO and Co-Founder of Nutriband Inc. (NASDAQ: NTRB), in what may be one of his final interviews before temporarily stepping aside to run for President of Ireland.

We dive deep into the company's groundbreaking AVERSA technology and its path to becoming the world's first abuse-deterrent transdermal patch.

What You'll Learn:

• How AVERSA technology could revolutionize opioid safety while preserving patient access to critical pain medications
• The strategic significance of Nutriband's exclusive partnership with Kindeva Drug Delivery and what it means for commercialization timelines
• Why analysts project AVERSA Fentanyl could capture $200-500M in peak annual sales
• How the company's unique regulatory pathway could slash traditional drug development costs and timelines
• BREAKING: Fresh insights on Nutriband's recent $5.3M warrant exercise and what this capital infusion means for their 2025 clinical milestones
• EXCLUSIVE: Sheridan's perspective on leadership transition as Co-Founder Serguei Melnik takes over as interim CEO during the Irish Presidential campaign

Sheridan reveals the company's ambitious 2025 roadmap, including plans for a pivotal Human Abuse Liability (HAL) clinical trial, and explains how Nutriband's manufacturing subsidiary is generating revenue while advancing their core pharmaceutical pipeline. With patents now secured across 46 countries and a 37% three-year return for investors, discover why this Orlando-based biotech believes they're positioned to capture a massive unmet need in pain management—and how the leadership transition will ensure continuity during this critical development phase.

Perfect for: Biotech investors, pharmaceutical industry professionals, and anyone interested in innovative solutions to the opioid crisis.

Key Topics: Abuse-deterrent drug technology, FDA regulatory pathways, biotech commercialization strategy, opioid market dynamics, pharmaceutical partnerships, executive leadership transitions

This episode was recorded just weeks before Sheridan's announcement to run for Irish President and step aside as CEO for the campaign period (September-October 2025).

Disclaimer:

The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned. The content of this podcast does not constitute investment, legal, or tax advice.

Any strategies or investment ideas discussed may not be suitable for all investors. Listeners should conduct their own research and consult with professional advisors before making any investment decisions. Past performance is not indicative of future results.

The host, guests, and producers of this podcast may hold positions in the securities discussed. This podcast may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements. Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate.

By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.

Always do your own due diligence and invest responsibly.